H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Pliant Therapeutics to $48 from $52 and keeps a Buy rating on the shares. After initially encouraging results in primary sclerosing cholangitis, the bexotegrast 320 mg data “are rather anticlimactic,” the analyst tells investors in a research note. The firm says these results weaken the prospects of the Pliant’s PSC program.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PLRX:
- Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
- The biotech stocks to own in 2024, according to Piper Sandler
- Pliant Therapeutics initiated with an Overweight at Wells Fargo